PQA has appointed 18 individuals to serve on a measure development technical expert panel (TEP) to support the development of a new health plan measure: Evidence of Guideline-Directed Medical Therapy in Persons with Heart Failure. This measure will assess the percentage of individuals with prescription claims for guideline-directed medical therapies for the treatment of heart failure.
PQA Is Launching a Heart Failure Technical Expert Panel
PQA convenes two standing technical expert panels – the Quality Metrics Expert Panel (QMEP) and Measure Update Panel (MUP) – to support PQA’s systematic, transparent, and consensus-based process for measure development and maintenance.
PQA has appointed individuals from member organizations to serve on the 2026 PQA Measure Update Panel (MUP) and Quality Metrics Expert Panel (QMEP).
Early in the measure life cycle, PQA solicits multi-stakeholder input to evaluate and prioritize health plan measure concepts for future development. To support measure conceptualization in 2025, PQA convened a Measure Concept Advisory Group (MCAG) and conducted a public comment period to inform future measure development, with a particular focus on addressing meaningful gaps in medication use quality while ensuring measure concepts are evidence-based and usable in real-world settings.
Health outcomes can be influenced by many factors other than the health care services received, including patient-related characteristics that are both clinical (i.e., pre-existing conditions) and non-clinical (e.g., income, education, age, race or ethnicity). Careful evaluation of risk adjustment is an important consideration to ensure that organizations that care for disadvantaged populations are measured fairly.
PQA has appointed 23 individuals to serve on a Measure Concept Advisory Group (MCAG) to help the organization to review and provide input on health plan measure concepts for future development. The group will provide guidance to prioritize areas of interest and potential measure concepts, evaluating key criteria such as:
PQA is launching a Health Plan Measure Concept Advisory Group (MCAG) to review and provide input on measure concepts for development in 2026 and beyond. The group will provide guidance to prioritize health plan measure concepts, evaluating key criteria such as:
PQA has appointed individuals from member organizations to serve on the 2025 PQA Measure Update Panel (MUP) and Quality Metrics Expert Panel (QMEP).
Chronic obstructive pulmonary disease (COPD) is a serious global health concern impacting millions of individuals. Despite being the third leading cause of mortality worldwide, COPD remains underdiagnosed and undertreated. Quality measures are a vital component of value-based payment models, but there are few COPD measures in current U.S. quality reporting programs, despite the established burden of COPD.
The use of specialty medicine has grown rapidly in recent decades, fueling parallel growth in the number of specialty pharmacies that serve patients who are prescribed specialty medications. Patients receiving specialty medications often have complex, high-cost treatment needs, necessitating close management from care teams, including specialty pharmacies. Specialty pharmacies dispense medications, for which timely initiation of therapy is a clinical priority to optimize outcomes.
Insulin persistence is associated with positive health and economic outcomes, according to a study conducted by researchers at the University of Mississippi, the Pharmacy Quality Alliance (PQA), and Ohio Northern University, the results of which were published in Clinical Diabetes in December of 2023. The study highlights the promising applicability of a method to measure insulin persistence at the population level. This same method is the foundation for PQA’s Persistence to Basal Insulin (PST-INS) health plan performance measure.
PQA has appointed individuals from member organizations to serve on the 2024 PQA Measure Update Panel (MUP) and Quality Metrics Expert Panel (QMEP).
PQA is working with its members and the broader medication therapy management (MTM) community to build consensus on the research, measurement and strategies needed to evolve our national approach to evaluating MTM service quality.
Diabetes is a chronic health condition that affects how the body produces or uses insulin, the hormone that regulates blood sugar.1 In the US, 34.2 million adults have diabetes, and 1 in 5 are unaware of their diagnosis.2 Medication is a mainstay in diabetes treatment, and a wide variety of medication classes are used to manage the disease.
Registration has opened for “PQA Convenes: Advancing Medication Therapy Management Quality Measurement,” which will take place on Thursday, November 2 in Arlington, Va. This invite-only event will bring together PQA members and industry experts to discuss the state of medication therapy management (MTM) practice, implications of recent Centers for Medicare & Medicaid Services (CMS) proposals and opportunities to evolve MTM quality measurement.
The Pharmacy Quality Alliance (PQA) seeks interested pharmacy and payer partners to participate in proof-of-concept pilots to implement and test high priority immunization pharmacy measure concepts.
PQA has launched the PQA Quality Innovation and Research Initiative to Advance Medication Therapy Management Quality Measurement – a national initiative to advance medication therapy management (MTM) quality measurement and other strategies to evaluate MTM services.
PQA has appointed 16 individuals from member organizations to serve on a technical expert panel (TEP) to review and provide input on draft specifications for the pharmacy measure concept, Specialty Pharmacy Prescription Abandonment Rate [Pharmacy] (SP-AR-PH).
PQA has appointed 19 individuals from member organizations to serve on a technical expert panel (TEP) to review and provide input on specific approaches to ensuring PQA’s measures support equitable health care.
